HILPDA and cancer: Depletion of ATGL reversed the effects of HIG2 knockout, suggesting that HIG2-mediated ATGL inhibition enables the survival of hypoxic cancer cells by reducing lipid droplet degradation and sequestering FAs away from mitochondrial oxidative and ROS-producing pathways [205].